XenTech Acknowledged in Deloitte’s 2012 Technology Fast 500™ EMEA for 2nd Year Running

Xentech the biotechnology company and CRO specialist in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets – is delighted to announce that it has been recognized in the prestigious 2012 Deloitte Technology Fast 500™ EMEA for the second year running. This recognition, places XenTech amongst the 500 fastest growing technology companies in Europe, Middle East and Africa.

This acknowledgement by Deloitte is determined by revenue growth figures over the previous five years of trading.

Established in 2006, relatively new XenTech see the credit for substantial growth – for two consecutive years – as a major triumph. It believes there are many factors for the achievement, including its efforts in innovation, scientific developments and expertise in the field of preclinical oncology and patient-derived tumor xenografts (PDX) along with the strong partner relationships it has established.

About Xentech
XenTech is an innovative biotech/CRO company specialising in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. It offers a unique collection of patient-derived tumor xenografts (PDX). PDX closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, genomics and drug response.

Its PDX models are extensively characterized and are associated to molecular data including gene expression and copy number data. Its preclinical platform is of considerable value for translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine. XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research. XenTech also develops internal oncology biomarker programs to correlate drug response with molecular features of tumors.

XenTech is known worldwide for its renowned oncology translational platform, its unique panel of patient-derived breast cancer xenografts and its extremely experienced scientific team.

About Deloitte Technology Fast 500™ EMEA
The Deloitte Technology Fast 500 EMEA program is the region’s most objective industry-ranking to focus on the technology field, recognizing technology companies that have achieved the fastest rates of revenue growth in Europe, the Middle East, and Africa (EMEA) during the past five years. The program is supported by the Deloitte Technology Fast 50 initiatives, which rank high growth technology companies by location or specifically defined geographic area and is run by the Deloitte Touche Tohmatsu Limited’s Technology, Media & Telecommunications (TMT) global industry group. Co-sponsors include Taylor Wessing, a leading International law firm with a focus on the industries of tomorrow, and Fidelity Growth Partners Europe, a venture and growth capital investor which backs entrepreneurs with aspiration for greatness in the IT and clean technology sectors across Europe.

For more information or to discuss XenTech being acknowledged in Deloitte’s 2012 Technology Fast 500™ EMEA please contact us directly.